Platinum-containing cytotoxic metabolite

The term "cytotoxic platinum-containing metabolites" is not a canonical name for a specific molecular target or receptor. Instead, it refers broadly to the active forms or breakdown products generated from **platinum-based chemotherapeutic drugs** such as cisplatin, carboplatin, oxaliplatin, nedaplatin, and lobaplatin. These agents are widely used in cancer therapy due to their ability to form covalent bonds with DNA bases—primarily at the N7 position of guanine—resulting in various types of DNA crosslinks that disrupt replication and transcription processes. This leads to cell cycle arrest and triggers programmed cell death pathways such as apoptosis[1][2][3][4][6]. Platinum compounds are not themselves biological targets; rather they act on cellular macromolecules like DNA. Their cytotoxic effects stem from their chemical reactivity rather than interaction with a defined protein target such as an enzyme or receptor. Some newer platinum complexes may exert effects through non-DNA mechanisms as well[5]. The efficacy of these drugs is often limited by acquired resistance mechanisms within tumor cells—including increased drug efflux via transporters like ATP7A/B or MRP2; enhanced detoxification by glutathione/metallothionein; improved repair capacity for platinum-induced lesions; reduced apoptotic response; or altered autophagy pathways[3]. Because "cytotoxic platinum-containing metabolites" does not refer to a single molecule but rather describes the class effect/metabolites produced by several related drugs—and because it does not represent a discrete therapeutic target—the entry is considered incorrect for structured molecular targeting purposes. "DNA is believed to be the molecular target for the cytotoxic activities of platinum anticancer drugs... pyrodach‐2 follows different cytotoxic mechanisms than does cisplatin... Results presented in this article represent a clear paradigm shift not only in expanding the molecular targets for Pt anticancer drugs but also in strategic development for more effective anticancer drugs."[5]

Other names

Platinum-based antineoplastic agentPlatinum-based chemotherapy drugPlatinsPlatinum compound (cisplatin/carboplatin/oxaliplatin)

Formation of platinum–DNA adducts leading to DNA crosslinking (intrastrand and interstrand) Inhibition of DNA repair and synthesis, resulting in cell cycle arrest and apoptosis[2][3][4][6] Induction of immunogenic cell death[2]